AgomAb Therapeutics NV: Redmile Group, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Redmile Group, LLC amended its Schedule 13G stake filing for AgomAb Therapeutics NV, disclosing the change to the SEC under accession number 0000905148-26-004929. The filing updates Redmile's previously reported beneficial ownership position in the Belgian biotech, though the amended disclosure did not specify a revised share count or percentage in the headline details. Schedule 13G amendments are typically filed by passive institutional investors when their holdings cross or adjust around the 5% threshold, making the update a signal of Redmile's current exposure to AgomAb. Investors should watch for the full filing text to confirm the exact size and direction of the position change, and for any subsequent 13F or 13G updates that clarify Redmile's intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
AgomAb Therapeutics NV, Redmile Group, LLC